The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets

An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.

In parallel with the new models and altered expectations taking shape in the post-apocalyptic venture capital world, certain platform-based biotechs are reviving the spirit of adventure that flagged in recent years as the economy soured and many investors dived for the cover of non-research, development-only companies (NARDOs). Many of these innovative platform plays were founded in the midst of the financial meltdown, supported by venture capital groups that stayed the course on early-stage companies. ( See Exhibit 1.)

This cohort of biotechs aims to develop platforms that can generate products against difficult targets Big Pharma is no longer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.